<DOC>
	<DOCNO>NCT01082809</DOCNO>
	<brief_summary>The purpose study determine whether sunitinib second-line treatment advance biliary tract carcinoma</brief_summary>
	<brief_title>Sunitinib Second-line Treatment Advanced Biliary Tract Carcinoma</brief_title>
	<detailed_description>Phase II study sunitinib second-line treatment advance biliary tract carcinoma : multicenter , multinational study</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1. age â‰¥ 18 2. histologically cytologically confirm adenocarcinoma biliary tract 3. unresectable metastatic 4 . ECOG performance status 0~2 5. measurable evaluable lesion per RECIST criterion 6. adequate marrow , hepatic , renal cardiac function 7 . One prior treatment cytotoxic chemotherapy ( include adjuvant treatment within 12 month ) 8. provision sign write informed consent 1. severe comorbid illness and/or active infection 2. pregnant lactate woman 3. active CNS metastasis controllable radiotherapy corticosteroid 4. known history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>advanced biliary tract carcinoma</keyword>
	<keyword>Sunitinib</keyword>
</DOC>